A Phase III, multicenter, randomized, two-armed, double-blind, parallel, active-controlled, non-inferiority clinical trial to compare efficacy and safety of test-Aflibercept (CinnaGen Co, Iran) to the reference Aflibercept product (Eylea, Regeneron, USA) in patients with Neovascular age-related macular degeneration
Latest Information Update: 16 Feb 2023
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Sponsors CinnaGen
Most Recent Events
- 16 Oct 2022 Status changed from active, no longer recruiting to completed.
- 30 Nov 2020 Status changed from recruiting to active, no longer recruiting.
- 24 Sep 2019 New trial record